Table 2.

Primary assessments of the ASSURE-CSU study

Medical record data	Patient-reported data
Demographic characteristics	Impact of disease tools:
	• EQ-5D-3L
	• DLQI
	• CU-Q2oL
	• AE-QoL (in patients with angioedema)
Baseline medical history	Angioedema history and characterization
Treatment received for CSU/CIU	Healthcare resource utilization (other than that recorded in charts, use of alternative medications and out-of-pocket expenses)
Duration of treatments	Disease activity (UAS7)
Total healthcare resource utilization	Work days and productivity loss (WPAI-SHP)

EQ-5D-3L three-level EuroQoL-5D, DLQI Dermatology Life Quality Index, CU-Q2oL Chronic Urticaria Quality-of-Life Questionnaire, AE-QoL Angioedema Quality-of-Life Questionnaire, CSU chronic spontaneous urticaria, UAS7 Weekly Urticaria Activity Score, WPAI-SHP Work Productivity and Activity Impairment – Specific Health Problems